AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35781462 — intervention group
Group type: EXPERIMENTAL
Intervention: PL‐5 spray
Number of subjects: 220
Study 33893842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 80
Study 33893842 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting diode therapy (LEDT)
Number of subjects: 80
Study 33893842 — intervention group
Group type: COMPARATOR
Intervention: Both LLLT and LEDT
Number of subjects: 80
Study 32407451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib treatment
Number of subjects: 244
Study 35801741 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐hour 1 + 2L bowel preparation regimen
Number of subjects: 600
Study 35801741 — intervention group
Group type: COMPARATOR
Intervention: 6‐hour 1 + 2L bowel preparation regimen
Number of subjects: 600
Study 35801741 — intervention group
Group type: COMPARATOR
Intervention: 4‐hour 0 + 2L bowel preparation regimen
Number of subjects: 600
Study 34034372 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS group (group E)
Number of subjects: 90
Study 32297095 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game integrated with PATHS curriculum
Number of subjects: 1526
Study 32297095 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game only
Number of subjects: 1526
Study 32297095 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1526
Study 34724085 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose radiotherapy (3.0 Gy total, 0.5 Gy twice weekly)
Number of subjects: 236
Study 34724085 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-dose radiotherapy (0.3 Gy total, 0.05 Gy twice weekly)
Number of subjects: 236
Study 33374006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine (specific dosage not mentioned)
Number of subjects: 173
Study 33011172 — intervention group
Group type: EXPERIMENTAL
Intervention: LHe 5.6 M
Number of subjects: 0
Study 33011172 — intervention group
Group type: COMPARATOR
Intervention: LN 5.6 M
Number of subjects: 0
Study 33011172 — intervention group
Group type: EXPERIMENTAL
Intervention: LN 6.6 M
Number of subjects: 0
Study 33011172 — intervention group
Group type: EXPERIMENTAL
Intervention: LHe 6.6 M
Number of subjects: 0
Study 33011172 — intervention group
Group type: EXPERIMENTAL
Intervention: LHe (−269 °C)
Number of subjects: 0
Study 33011172 — intervention group
Group type: EXPERIMENTAL
Intervention: LN (−196 °C)
Number of subjects: 0
Study 35140514 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine during anaesthesia
Number of subjects: 96
Study 35140514 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) during anaesthesia
Number of subjects: 96
Study 34086447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation intervention (household latrines)
Number of subjects: 0
Study 34086447 — intervention group
Group type: COMPARATOR
Intervention: Control (no sanitation intervention)
Number of subjects: 0
Study 32056507 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based implant motion analysis (CTMA) using surface anatomy of the pelvis
Number of subjects: 24
Study 32056507 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based implant motion analysis (CTMA) using beads
Number of subjects: 24
Study 32056507 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based implant motion analysis (CTMA)
Number of subjects: 24
Study 34432089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh hysteropexy
Number of subjects: 175
Study 34432089 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 175
Study 32297782 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/mL nicotine e‐liquid
Number of subjects: 49
Study 32297782 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/mL nicotine e‐liquid
Number of subjects: 49
Study 32297782 — intervention group
Group type: EXPERIMENTAL
Intervention: Green apple e‐liquid
Number of subjects: 49
Study 32297782 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol e‐liquid
Number of subjects: 49
Study 32297782 — intervention group
Group type: COMPARATOR
Intervention: Unflavored e‐liquid
Number of subjects: 49
Study 32122230 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg b.i.d.)
Number of subjects: 78
Study 32122230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 36307493 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligo-fucoidan
Number of subjects: 20
Study 36307493 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 20
Study 33115675 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil
Number of subjects: 30
Study 33115675 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 30
Study 33115675 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 32390339 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program (SMP) intervention for 4 weeks
Number of subjects: 58
Study 32390339 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 34301736 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized postprandial-targeting (PPT) diet
Number of subjects: 225
Study 34301736 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean (MED) diet
Number of subjects: 225
Study 35754324 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual clinic
Number of subjects: 96
Study 35754324 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient clinical care (Control)
Number of subjects: 96
Study 35754324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 33739883 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR‐2 (900 mg per day for 8 weeks)
Number of subjects: 88
Study 33739883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (900 mg per day for 8 weeks)
Number of subjects: 88
Study 34282977 — intervention group
Group type: EXPERIMENTAL
Intervention: RPT (Relationship Profile Test)
Number of subjects: 661
Study 33774921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 1034
Study 33774921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1034
Study 32169310 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IGF-1 concentrations
Number of subjects: 206263
Study 32169310 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-predicted IGF-1 concentration
Number of subjects: 206263
Study 32169310 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-predicted IGFBP-3 concentrations
Number of subjects: 206263
Study 35872448 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS stimulation (anodal electrical stimulation at 2 mA for 20 min once daily for 7 days)
Number of subjects: 24
Study 35872448 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 24
Study 35872448 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS stimulation
Number of subjects: 24
Study 32730170 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic Organizers (GOs)
Number of subjects: 59
Study 32730170 — intervention group
Group type: COMPARATOR
Intervention: Flash Cards (FCs)
Number of subjects: 59
Study 32227142 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (audit feedback with targeted suggestions, a 7-week quality improvement collaborative, and best-practice sharing)
Number of subjects: 864080
Study 32227142 — intervention group
Group type: COMPARATOR
Intervention: Audit feedback alone
Number of subjects: 864080
Study 34137239 — intervention group
Group type: EXPERIMENTAL
Intervention: Left distal transradial angiography (ldTRA)
Number of subjects: 57
Study 34137239 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral angiography (TFA)
Number of subjects: 57
Study 33395671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained attention to response task (SART) in ALS patients
Number of subjects: 57
Study 33395671 — intervention group
Group type: COMPARATOR
Intervention: SART in healthy controls
Number of subjects: 57
Study 33395671 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-band ERD in ALS patients
Number of subjects: 57
Study 33395671 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ECAS ALS-specific scores in ALS patients
Number of subjects: 57
Study 32723374 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 34
Study 32723374 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl placebo
Number of subjects: 34
Study 35522399 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care only (SMC)
Number of subjects: 115
Study 35522399 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations optimization (EXPECT)
Number of subjects: 115
Study 35522399 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 115
Study 33550243 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral DHA supplementation (60 mg/kg/day)
Number of subjects: 1273
Study 33550243 — intervention group
Group type: COMPARATOR
Intervention: Control emulsion (without DHA)
Number of subjects: 1273
Study 33550243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive assessment at 5 years of age
Number of subjects: 1273
Study 34613973 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) combined with physiotherapeutic exercises
Number of subjects: 30
Study 34613973 — intervention group
Group type: COMPARATOR
Intervention: Sham PBM combined with physiotherapeutic exercises
Number of subjects: 30
Study 32859615 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 139
Study 32859615 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 139
Study 32859615 — intervention group
Group type: COMPARATOR
Intervention: Exercise and Metformin
Number of subjects: 139
Study 35464450 — intervention group
Group type: EXPERIMENTAL
Intervention: OVX836 (180µg)
Number of subjects: 300
Study 35464450 — intervention group
Group type: EXPERIMENTAL
Intervention: OVX836 (90µg)
Number of subjects: 300
Study 35464450 — intervention group
Group type: COMPARATOR
Intervention: Influvac Tetra (control)
Number of subjects: 300
Study 33033956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol box
Number of subjects: 38
Study 33033956 — intervention group
Group type: COMPARATOR
Intervention: No aerosol box
Number of subjects: 38
Study 33033956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol box (normal airway)
Number of subjects: 38
Study 33033956 — intervention group
Group type: COMPARATOR
Intervention: No aerosol box (normal airway)
Number of subjects: 38
Study 33033956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol box (difficult airway)
Number of subjects: 38
Study 33033956 — intervention group
Group type: COMPARATOR
Intervention: No aerosol box (difficult airway)
Number of subjects: 38
Study 33814393 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable dental splint-teethguard
Number of subjects: 60
Study 33814393 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable splint-teethguards and transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 60
Study 32451320 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCHMAN
Number of subjects: 641
Study 32451320 — intervention group
Group type: COMPARATOR
Intervention: ACP/Amulet
Number of subjects: 641
Study 36173147 — intervention group
Group type: EXPERIMENTAL
Intervention: SKILLZ Health for Girls programme (sports-based sexual education intervention)
Number of subjects: 38
Study 33493373 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 3
Study 33493373 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with an opioid
Number of subjects: 3
Study 32282379 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported harmful medical error
Number of subjects: 0
Study 32282379 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported near miss medical error
Number of subjects: 0
Study 32282379 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout symptoms
Number of subjects: 0
Study 32282379 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor psychiatric well-being
Number of subjects: 0
Study 32282379 — intervention group
Group type: COMPARATOR
Intervention: Program-level resident wellness
Number of subjects: 0
Study 36172693 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rtCGM) with alert functionality
Number of subjects: 0
Study 36172693 — intervention group
Group type: COMPARATOR
Intervention: Intermittently scanned continuous glucose monitoring (isCGM) without alerts
Number of subjects: 0
Study 36172693 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rtCGM)
Number of subjects: 0
Study 34769707 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based smoking cessation intervention
Number of subjects: 403
Study 32352250 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate gel 0.5%
Number of subjects: 105
Study 32352250 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate suspension 1%
Number of subjects: 105
Study 35727234 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-mouth trials
Number of subjects: 244
Study 33467876 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting instructions (n=36)
Number of subjects: 72
Study 33467876 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions (n=36)
Number of subjects: 72
Study 35511296 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 47
Study 35511296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 34404290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 0
Study 34404290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin augmentation
Number of subjects: 0
Study 34404290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin augmentation of antipsychotics
Number of subjects: 0
Study 32920219 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with perinephric fat stranding (PFS) - Group A (38 patients)
Number of subjects: 82
Study 32920219 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without perinephric fat stranding (PFS) - Group B (44 patients)
Number of subjects: 82
Study 32920219 — intervention group
Group type: COMPARATOR
Intervention: Control group (80 subjects with no kidney diseases)
Number of subjects: 82
Study 32920219 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 82
Study 34679162 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Varnish applied every 4-6 weeks
Number of subjects: 40
Study 34679162 — intervention group
Group type: COMPARATOR
Intervention: ProSeal sealant with reapplications every 3 months
Number of subjects: 40
Study 32869527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV self-tests (HIVST) distributed in intervention clusters
Number of subjects: 2671
Study 32869527 — intervention group
Group type: COMPARATOR
Intervention: Control group with no self-tests distributed
Number of subjects: 2671
Study 33118847 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod
Number of subjects: 66
Study 33118847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 32871534 — intervention group
Group type: EXPERIMENTAL
Intervention: six IV ketamine
Number of subjects: 0
Study 32871534 — intervention group
Group type: COMPARATOR
Intervention: single IV ketamine
Number of subjects: 0
Study 32871534 — intervention group
Group type: COMPARATOR
Intervention: five IV midazolam followed by a single IV ketamine
Number of subjects: 0
Study 36408722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored digitally enabled exercise intervention
Number of subjects: 300
Study 36408722 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 300
Study 33574125 — intervention group
Group type: EXPERIMENTAL
Intervention: Imeglimin (1,000 mg twice daily)
Number of subjects: 213
Study 33574125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 32044975 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic visual inspection (AVI alone)
Number of subjects: 11
Study 32044975 — intervention group
Group type: COMPARATOR
Intervention: Angiographic visual inspection plus fractional flow reserve (AVI plus FFR)
Number of subjects: 11
Study 35066653 — intervention group
Group type: EXPERIMENTAL
Intervention: R-LPS (laboratory prognostic score) based on 8 indices
Number of subjects: 649
Study 35066653 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 independent prognostic factors for 14-day survival
Number of subjects: 649
Study 32789898 — intervention group
Group type: EXPERIMENTAL
Intervention: SITall-out (n = 11)
Number of subjects: 59
Study 32789898 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT120 (n = 12)
Number of subjects: 59
Study 32789898 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT90 (n = 12)
Number of subjects: 59
Study 32789898 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT (n = 11)
Number of subjects: 59
Study 32789898 — intervention group
Group type: COMPARATOR
Intervention: CON (n = 13)
Number of subjects: 59
Study 35796215 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 0
Study 35796215 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face cognitive behavioral therapy (CBT)
Number of subjects: 0
Study 32752234 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual physiotherapy
Number of subjects: 136
Study 32752234 — intervention group
Group type: COMPARATOR
Intervention: Group physiotherapy
Number of subjects: 136
Study 32752234 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analysis (data carried forward from week 12)
Number of subjects: 136
Study 35656851 — intervention group
Group type: EXPERIMENTAL
Intervention: Refill-based opioid prescription method (experimental arm)
Number of subjects: 48
Study 35656851 — intervention group
Group type: COMPARATOR
Intervention: Control arm (single prescription for all postoperative narcotics)
Number of subjects: 48
Study 33637058 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital handle
Number of subjects: 567
Study 33637058 — intervention group
Group type: COMPARATOR
Intervention: Conventional handle
Number of subjects: 567
Study 32665040 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2440
Study 32665040 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir (400mg) / Ritonavir (100mg) twice daily for 10 days
Number of subjects: 2440
Study 32665040 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (800mg on Day 1, followed by 400mg twice a day for 6 days)
Number of subjects: 2440
Study 32665040 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir plus Hydroxychloroquine
Number of subjects: 2440
Study 36501136 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-Virgin Olive Oil (EVOO)
Number of subjects: 26
Study 36501136 — intervention group
Group type: COMPARATOR
Intervention: Refined Olive Oil (ROO)
Number of subjects: 26
Study 36501136 — intervention group
Group type: COMPARATOR
Intervention: EVOO and ROO
Number of subjects: 26
Study 33628403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb joint nursing and rehabilitation system based on intelligent medical treatment
Number of subjects: 55
Study 33382931 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin threshold for red-cell transfusion
Number of subjects: 1824
Study 33382931 — intervention group
Group type: COMPARATOR
Intervention: Lower hemoglobin threshold for red-cell transfusion
Number of subjects: 1824
Study 34075872 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prescribing for respiratory tract diagnoses (RTDs)
Number of subjects: 1200
Study 34075872 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrics utilizing prespecified RTDs
Number of subjects: 1200
Study 34075872 — intervention group
Group type: COMPARATOR
Intervention: APP versus physician
Number of subjects: 1200
Study 34075872 — intervention group
Group type: COMPARATOR
Intervention: Family medicine versus internal medicine
Number of subjects: 1200
Study 34075872 — intervention group
Group type: COMPARATOR
Intervention: Board certification 1997 or later versus before 1997
Number of subjects: 1200
Study 34075872 — intervention group
Group type: COMPARATOR
Intervention: Nonteaching versus teaching practice
Number of subjects: 1200
Study 34075872 — intervention group
Group type: COMPARATOR
Intervention: Nonurban versus urban practice
Number of subjects: 1200
Study 33988948 — intervention group
Group type: EXPERIMENTAL
Intervention: PKP + FJB
Number of subjects: 194
Study 33988948 — intervention group
Group type: COMPARATOR
Intervention: PKP
Number of subjects: 194
Study 34038624 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure walking
Number of subjects: 66
Study 34038624 — intervention group
Group type: COMPARATOR
Intervention: Self-chosen activity at home (Control)
Number of subjects: 66
Study 32881712 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back stretch
Number of subjects: 22
Study 32881712 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist stretch
Number of subjects: 22
Study 33493833 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndecan-1 levels at baseline (T0)
Number of subjects: 95
Study 33493833 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndecan-1 levels at T0 and T6
Number of subjects: 95
Study 33493833 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndecan-1 levels at T6
Number of subjects: 95
Study 32473959 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised cancer risk information (bar chart, pictograph, qualitative scale) alongside cancer-specific lifestyle advice
Number of subjects: 1018
Study 32473959 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving cancer-specific lifestyle advice
Number of subjects: 1018
Study 35636341 — intervention group
Group type: COMPARATOR
Intervention: TP (Trastuzumab and Pertuzumab)
Number of subjects: 80
Study 35636341 — intervention group
Group type: EXPERIMENTAL
Intervention: TPM (metronomic oral cyclophosphamide + Trastuzumab + Pertuzumab)
Number of subjects: 80
Study 35636341 — intervention group
Group type: COMPARATOR
Intervention: TP
Number of subjects: 80
Study 35636341 — intervention group
Group type: EXPERIMENTAL
Intervention: TPM
Number of subjects: 80
Study 35636341 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 after progression
Number of subjects: 80